Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

作者：Melissa D. Barnes, Vijay Kumar, Christopher R. Bethel, Samir H. Moussa, John P. O’Donnell, Joseph Rutter, Caryn E. Good, Kristine M. Hujer, Andrea M. Hujer, Steve H. Marshall, Barry N. Kreiswirth, Sandra S. Richter, Philip N. Rather, Michael R. Jacobs, Krisztina M. Papp‐Wallace, Focco van den Akker, Robert A. Bonomo · 发表于：mBio · 年份：2019 · DOI：10.1128/mbio.00159-19 · 被引用次数：120 · 研究领域：Antibiotic Resistance in Bacteria、Pharmaceutical and Antibiotic Environmental Impacts、Antibiotics Pharmacokinetics and Efficacy

The number and diversity of β-lactamases are steadily increasing. The emergence of β-lactamases that hydrolyze carbapenems poses a significant threat to our antibiotic armamentarium. The explosion of OXA enzymes that are carbapenem hydrolyzers is a major challenge (carbapenem-hydrolyzing class D [CHD]). An urgent need exists to discover β-lactamase inhibitors with class D activity. The sulbactam-ETX2514 combination demonstrates the potential to become a treatment regimen of choice for Acinetobacter spp. producing class D β-lactamases.